Asaf Zviran
Co-founder, CEO @Prism Ai Therapeutics
Signup · Get unlimited contacts
WORK HISTORY
Co-founder, CEO @Prism Ai Therapeutics
US
The ability to detect and target complex multi-omics signatures is the basis for personalized medicine. But typical AI cannot discover effective biomarkers from real-life clinical trial data. Prism AI’s cloud computing platform provides a powerful and novel AI approach expertly designed for biomarker discovery, companion diagnostics (CDx), and drug target identification from raw, real-time clinical trial data. We specialize in extracting novel insights from label-free (unsupervised), small patient cohort sizes and multi-omics data, ensuring data harmonization and systemic batch effect corrections across diverse sites, collection protocols, demographic variables, and measurement platforms. Our patented technology, based on quantum mechanics, has produced multiple novel oncology biomarkers that have been clinically proven to be the most accurate and precise in peer-reviewed publications.
EDUCATION
Technion - Israel Institute of Technology
Bachelor of Science (BSc), Electrical Engineering & Physics
Weizmann Institute of Science
Doctor of Philosophy (Ph.D.), Molecular Biology
Psagot
Electrical Engineering & Physics
Joan & Sanford I. Weill Medical College of Cornell University
Postdoctoral Research, Biotechnology
Technion - Israel Institute of Technology
Master of Science (MSc), Operations Research
SKILLS
ABOUT ASAF ZVIRAN
Experienced entrepreneur, scientist, and executive with over 20 years of product…
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.